- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101 dermal cream (6%)
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 54
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Dystrophica
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Spincare matrix
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- AGLE-102
- Drug
- Lead sponsor
- Aegle Therapeutics
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Prademagene Zamikeracel
- Combination Product
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2045
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Granulocyte Colony Stimulating Factor (GCSF)
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Topical beremagene geperpavec, Placebo gel
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa
- Interventions
- Survey
- Other
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cranbury, New Jersey
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
- Interventions
- LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
- Interventions
- Apligraf, Standard dressing regimen
- Device · Other
- Lead sponsor
- Organogenesis
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 5
- States / cities
- Stanford, California • Miami, Florida • New York, New York + 2 more
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- KB803, Placebo
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Rancho Santa Margarita, California • Coral Gables, Florida • Worcester, Massachusetts + 2 more
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive
- Interventions
- FCX-007
- Genetic
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101-6.0 cream, Placebo (SD-101-0.0) cream
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Rigosertib Sodium, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Interventions
- Efgartigimod
- Biological
- Lead sponsor
- M. Peter Marinkovich
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101-6.0 cream
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin Sulfate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Open Label Topical Beremagene Geperpavec (B-VEC)
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- D-Fi
- Biological
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 4
- States / cities
- Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- Diacerein 1% Ointment
- Drug
- Lead sponsor
- Castle Creek Pharmaceuticals, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina